JP2023082086A5 - - Google Patents

Download PDF

Info

Publication number
JP2023082086A5
JP2023082086A5 JP2023052465A JP2023052465A JP2023082086A5 JP 2023082086 A5 JP2023082086 A5 JP 2023082086A5 JP 2023052465 A JP2023052465 A JP 2023052465A JP 2023052465 A JP2023052465 A JP 2023052465A JP 2023082086 A5 JP2023082086 A5 JP 2023082086A5
Authority
JP
Japan
Prior art keywords
crystalline form
powder
ray diffraction
pharmaceutical composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023052465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023082086A (ja
JP7763203B2 (ja
Filing date
Publication date
Priority claimed from JP2019538551A external-priority patent/JP7253491B2/ja
Application filed filed Critical
Publication of JP2023082086A publication Critical patent/JP2023082086A/ja
Publication of JP2023082086A5 publication Critical patent/JP2023082086A5/ja
Application granted granted Critical
Publication of JP7763203B2 publication Critical patent/JP7763203B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023052465A 2016-09-29 2023-03-28 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用 Active JP7763203B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201610866253 2016-09-29
CN201610866253.6 2016-09-29
JP2019538551A JP7253491B2 (ja) 2016-09-29 2017-09-29 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用
PCT/CN2017/104506 WO2018059556A1 (zh) 2016-09-29 2017-09-29 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019538551A Division JP7253491B2 (ja) 2016-09-29 2017-09-29 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用

Publications (3)

Publication Number Publication Date
JP2023082086A JP2023082086A (ja) 2023-06-13
JP2023082086A5 true JP2023082086A5 (OSRAM) 2023-07-28
JP7763203B2 JP7763203B2 (ja) 2025-10-31

Family

ID=61763329

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019538551A Active JP7253491B2 (ja) 2016-09-29 2017-09-29 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用
JP2023052465A Active JP7763203B2 (ja) 2016-09-29 2023-03-28 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019538551A Active JP7253491B2 (ja) 2016-09-29 2017-09-29 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用

Country Status (17)

Country Link
US (3) US11053224B2 (OSRAM)
EP (1) EP3502105B8 (OSRAM)
JP (2) JP7253491B2 (OSRAM)
KR (1) KR102289684B1 (OSRAM)
CN (1) CN108884080B (OSRAM)
AU (1) AU2017336889B2 (OSRAM)
CA (2) CA3253105A1 (OSRAM)
EA (1) EA201990688A1 (OSRAM)
ES (1) ES2914294T3 (OSRAM)
IL (2) IL311631A (OSRAM)
MY (1) MY194364A (OSRAM)
PH (1) PH12019500681A1 (OSRAM)
PL (1) PL3502105T3 (OSRAM)
SG (1) SG11201901962QA (OSRAM)
TW (1) TWI647224B (OSRAM)
WO (1) WO2018059556A1 (OSRAM)
ZA (1) ZA201901717B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3502105T3 (pl) * 2016-09-29 2022-07-11 Equinox Sciences, Llc. Postać polimorficzna związku stanowiącego inhibitor kinazy, zawierająca ją kompozycja farmaceutyczna oraz sposób jej wytwarzania i jej zastosowanie
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
DK3884929T3 (da) 2020-03-25 2023-09-25 Ocular Therapeutix Inc Øjenimplantat indeholdende en tyrosinkinase-inhibitor
IL301227A (en) 2020-09-14 2023-05-01 Eyepoint Pharmaceuticals Inc Supplement for administration of biologically respirable ophthalmic drugs and therapeutic method
US20240051957A1 (en) * 2021-03-16 2024-02-15 Hk Inno.N Corporation Crystalline form of heterocyclic compound as protein kinase inhibitor
JP7138982B1 (ja) 2021-09-24 2022-09-20 東海物産株式会社 アンセリンの結晶及びその製造方法
AU2023230975A1 (en) 2022-03-11 2024-09-19 EyePoint Pharmaceuticals, Inc. Method of preventing age-related macular degeneration by administering an ocular drug delivery insert
WO2023173095A1 (en) 2022-03-11 2023-09-14 EyePoint Pharmaceuticals, Inc. Method of treating wet age-related macular degeneration
EP4489750A1 (en) 2022-03-11 2025-01-15 EyePoint Pharmaceuticals, Inc. Continuous dosing regimen for treatment of a condition of the eye
WO2024215649A1 (en) 2023-04-11 2024-10-17 Ocular Therapeutix, Inc. Ocular implant comprising axitinib polymorph iv
CN117143083A (zh) * 2023-08-30 2023-12-01 沈阳药科大学 VEGFR抑制剂Vorolanib的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031438A1 (en) 2001-10-10 2003-04-17 Sugen, Inc. 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
JP5568304B2 (ja) * 2006-09-15 2014-08-06 タイロジェネクス,インコーポレイテッド キナーゼ阻害剤化合物
WO2008134909A1 (de) * 2007-05-07 2008-11-13 Baumer Electric Ag Akustischer wandler
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
US8466190B2 (en) * 2008-04-16 2013-06-18 Natco Pharma Limited Polymorphic forms of Sunitinib base
US8829039B2 (en) * 2008-05-23 2014-09-09 Shanghai Institute Of Pharmaceutical Industry Dihydroindolinone derivatives
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2264027A1 (en) * 2009-05-27 2010-12-22 Ratiopharm GmbH Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
CN106928114B (zh) * 2015-12-31 2020-07-28 韶远科技(上海)有限公司 含有脲基的环状手性氨基类化合物及其可放大工艺和用途
PL3502105T3 (pl) 2016-09-29 2022-07-11 Equinox Sciences, Llc. Postać polimorficzna związku stanowiącego inhibitor kinazy, zawierająca ją kompozycja farmaceutyczna oraz sposób jej wytwarzania i jej zastosowanie

Similar Documents

Publication Publication Date Title
JP2023082086A5 (OSRAM)
JP2021530565A5 (OSRAM)
JP2020512316A5 (OSRAM)
CN1227233C (zh) 纯晶形的5-氯-3-(4-甲磺酰基苯基)-6′-甲基-[2,3′]联吡啶及其合成方法
JP2005503386A5 (OSRAM)
JP2023002516A5 (OSRAM)
JP2009521414A5 (OSRAM)
JP2023036708A5 (OSRAM)
JP2022183220A5 (OSRAM)
JP2021514967A5 (OSRAM)
JP2019504103A5 (OSRAM)
JP2019516749A5 (OSRAM)
JP2007532560A5 (OSRAM)
AU2001264804A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
CN102964384B (zh) 阿德福韦酯没食子酸共晶及其制备方法和组合物
JP2011515421A5 (OSRAM)
JP2016510767A5 (OSRAM)
CN111278820A (zh) 一种吡啶酮化合物的晶型、盐型及其制备方法
JP2017503016A5 (OSRAM)
CA2447878C (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
CN113348166A (zh) 喹啉衍生物的结晶
JP2018024683A5 (OSRAM)
JPWO2020118113A5 (OSRAM)
JP2019500385A5 (OSRAM)
JPWO2022257845A5 (OSRAM)